LivaNova PLC (LIVN)
LIVN Stock Price Chart
Explore LivaNova PLC interactive price chart. Choose custom timeframes to analyze LIVN price movements and trends.
LIVN Company Profile
Discover essential business fundamentals and corporate details for LivaNova PLC (LIVN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
19 Oct 2015
Employees
2.90K
Website
https://www.livanova.comCEO
Vladimir A. Makatsaria
Description
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
LIVN Financial Timeline
Browse a chronological timeline of LivaNova PLC corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is $0.91, while revenue estimate is $342.32M.
Earnings released on 6 Aug 2025
EPS came in at $1.05 surpassing the estimated $0.84 by +25.00%, while revenue for the quarter reached $352.52M , beating expectations by +3.05%.
Earnings released on 7 May 2025
EPS came in at $0.88 surpassing the estimated $0.75 by +17.33%, while revenue for the quarter reached $316.86M , missing expectations by -4.23%.
Earnings released on 25 Feb 2025
EPS came in at $0.81 surpassing the estimated $0.80 by +1.25%, while revenue for the quarter reached $321.80M , beating expectations by +4.26%.
Earnings released on 30 Oct 2024
EPS came in at $0.90 surpassing the estimated $0.71 by +26.76%, while revenue for the quarter reached $318.12M , missing expectations by -1.71%.
Earnings released on 31 Jul 2024
EPS came in at $0.93 surpassing the estimated $0.79 by +17.72%, while revenue for the quarter reached $318.58M , beating expectations by +4.72%.
Earnings released on 1 May 2024
EPS came in at $0.73 surpassing the estimated $0.45 by +62.22%, while revenue for the quarter reached $294.91M , missing expectations by -3.06%.
Earnings released on 21 Feb 2024
EPS came in at $0.87 surpassing the estimated $0.79 by +10.13%, while revenue for the quarter reached $310.10M , beating expectations by +7.90%.
Earnings released on 1 Nov 2023
EPS came in at $0.73 surpassing the estimated $0.62 by +17.74%, while revenue for the quarter reached $286.10M , beating expectations by +4.64%.
Earnings released on 26 Jul 2023
EPS came in at $0.78 surpassing the estimated $0.58 by +34.48%, while revenue for the quarter reached $293.90M , beating expectations by +8.09%.
Earnings released on 3 May 2023
EPS came in at $0.43 surpassing the estimated $0.41 by +4.88%, while revenue for the quarter reached $263.40M , beating expectations by +8.21%.
Earnings released on 22 Feb 2023
EPS came in at $0.81 surpassing the estimated $0.72 by +12.50%, while revenue for the quarter reached $274.90M , beating expectations by +4.81%.
Earnings released on 2 Nov 2022
EPS came in at $0.58 surpassing the estimated $0.57 by +1.75%, while revenue for the quarter reached $252.61M , beating expectations by +2.27%.
Earnings released on 3 Aug 2022
EPS came in at $0.53 surpassing the estimated $0.51 by +3.92%, while revenue for the quarter reached $254.20M , beating expectations by +1.86%.
Earnings released on 4 May 2022
EPS came in at $0.48 falling short of the estimated $0.52 by -7.69%, while revenue for the quarter reached $240.18M , beating expectations by +3.72%.
Earnings released on 23 Feb 2022
EPS came in at $0.57 surpassing the estimated $0.50 by +14.00%, while revenue for the quarter reached $270.10M , beating expectations by +1.08%.
Earnings released on 3 Nov 2021
EPS came in at $0.68 surpassing the estimated $0.45 by +51.11%, while revenue for the quarter reached $253.22M , beating expectations by +3.17%.
Earnings released on 28 Jul 2021
EPS came in at $0.52 surpassing the estimated $0.32 by +62.50%, while revenue for the quarter reached $264.48M , beating expectations by +7.96%.
Earnings released on 28 Apr 2021
EPS came in at $0.35 surpassing the estimated $0.15 by +133.33%, while revenue for the quarter reached $247.60M , beating expectations by +21.21%.
Earnings released on 24 Feb 2021
EPS came in at $0.71 surpassing the estimated $0.66 by +7.58%, while revenue for the quarter reached $269.60M , beating expectations by +8.21%.
Earnings released on 29 Oct 2020
EPS came in at $0.38 surpassing the estimated $0.21 by +80.95%, while revenue for the quarter reached $240.08M , beating expectations by +19.72%.
LIVN Stock Performance
Access detailed LIVN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.